INCYTE CORP Earnings Summary — Q3 FY2026

• Incyte has transitioned into a vertically integrated commercial powerhouse with significant cash flow generation.
• The core JAK inhibitor Jakafi continues to dominate the MPN market, though focus is shifting to lifecycle management.
• Opzelura's successful launch in dermatology marks a strategic pivot to diversify revenue away from oncology concentration.
• The company maintains an exceptionally strong balance sheet with zero long-term debt and over $3 billion in cash.
• High R&D intensity remains a pillar of strategy, consuming 30-50% of revenue to address the upcoming Jakafi patent cliff.
• Strategic partnerships with Novartis and Eli Lilly continue to provide global reach and diversified milestone income.

Management remains focused on executing the dermatology launch for Opzelura and progressing the oncology pipeline to mitigate the impact of the ruxolitinib loss of exclusivity toward the end of the decade.

Stable

The business continues its steady transition from a research boutique to a profitable commercial entity with a diversifying product base.

The long-term outlook hinges on the commercial scaling of Opzelura and the success of the mid-to-late stage pipeline in overcoming upcoming patent expirations for Jakafi.